drugset / Trial / NCT00786643

Study of Gamma Interfereon in Metastatic Colorectal Carcinoma

NCT00786643

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evalute the response and toxicity of metastatic colorectal cancer patients to the regimen of gamma interferon added to bolus and infusional 5-fluorouracil and leucovorin (GFL) with or without bevacizumab.

Timeline

Start
2006-02
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 5 mg/kg
Subject Interferon gamma-1b Protein / enzyme biologic 150 ug/m2 Subcutaneous
Background Leucovorin Small molecule 200 mg/m2
Background fluorouracil Small molecule 400 mg/m2
Background fluorouracil Small molecule 600 mg/m2

Indications